The European Medicines Agency Has Approved a Paediatric Investigation Plan for an Experimental Treatment of Charcot-Marie-Tooth Disease Type 1A
The company Pharnext SA, which is developing the investigational drug PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A, has agreed upon a paediatric investigation plan for the drug with…